4-(rhamnosyloxy)phenylacetonitrile: from roasted seeds of Moringa oleifera; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Moringa | genus | A plant genus of the family Moringaceae, order Capparales, subclass Dilleniidae, class Magnoliopsida.[MeSH] | Moringaceae | [no description available] |
| ID Source | ID |
|---|---|
| PubMed CID | 129556 |
| CHEMBL ID | 446981 |
| CHEBI ID | 191636 |
| SCHEMBL ID | 4652379 |
| MeSH ID | M0166705 |
| Synonym |
|---|
| 4-(alpha-l-rhamnosyloxy)phenylacetonitrile |
| benzeneacetonitrile, 4-((6-deoxy-alpha-l-mannopyranosyl)oxy)- |
| 4-((6-deoxy-alpha-l-mannopyranosyl)oxy)benzeneacetonitrile |
| 4-(rhamnosyloxy)phenylacetonitrile |
| CHEMBL446981 |
| 122001-32-5 |
| 2-[4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphenyl]acetonitrile |
| CHEBI:191636 |
| niazirin |
| niazirine |
| SCHEMBL4652379 |
| DTXSID60153465 |
| 4(alpha-l-rhamnosyloxy) phenylacetonitrile |
| 2-[4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphenyl]acetonitrile |
| AKOS040762118 |
| 2-(4-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)phenyl)acetonitrile |
| Class | Description |
|---|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID502184 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated 30 mins prior to LPS challenge | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Potential anti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits. |
| AID502185 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 5 uM incubated 30 mins prior to LPS challenge | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Potential anti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits. |
| AID337326 | Hypotensive activity against normotensive anesthetized Wistar rat assessed as reduction in mean arterial blood pressure up to 5 ug/kg, iv | 1994 | Journal of natural products, Sep, Volume: 57, Issue:9 | Isolation and structure elucidation of new nitrile and mustard oil glycosides from Moringa oleifera and their effect on blood pressure. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||